Prasugrel Maleic acid

作者: 莫小枫 | 来源:发表于2017-11-30 15:01 被阅读0次

    "目录号: HY-15284B

    GPCR/G Protein-

    Prasugrel马来酸盐是是血小板抑制剂,IC50为1.8 μM。

    P2Y Receptor

    相关产品

    Suramin sodium salt-Clopidogrel hydrogen sulfate-Ticagrelor-MRS 2578-Prasugrel-AZD1283-N6-(4-Hydroxybenzyl)adenosine-Diquafosol tetrasodium-Denufosol tetrasodium-

    生物活性

    Description

    Prasugrel Maleic acid is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel Maleic acid is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel Maleic acid reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel Maleic acid AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia;  Nausea; Epistaxis

    Clinical Trial

    NCT02212028

    University of Florida

    Coronary Artery Disease

    October 2014

    Phase 4

    NCT01493999

    University of Pecs

    Acute Coronary Syndrome

    September 2011

    Phase 4

    NCT01260584

    Daiichi Sankyo Inc.

    Coronary Artery Disease

    November 2010

    Phase 4

    NCT01476696

    Eli Lilly and Company-Daiichi Sankyo Inc.

    Sickle Cell Disease

    November 2011

    Phase 2

    NCT01560780

    VA Office of Research and Development

    Coronary Artery Bypass

    February 1, 2013

    Phase 3

    NCT01115738

    Eli Lilly and Company

    Acute Coronary Syndrome

    May 2010

    Phase 2

    NCT01014624

    Daiichi Sankyo Inc.

    Coronary Artery Disease

    February 2010

    Phase 4

    NCT01201772

    University of Florida

    Coronary Artery Disease

    August 2010

    Phase 4

    NCT01835353

    University of Patras

    Platelet Reactivity

    June 2012

    Phase 3

    NCT01178099

    Eli Lilly and Company-Daiichi Sankyo Co., Ltd.

    Anemia, Sickle Cell

    July 2010

    Phase 1

    NCT01852175

    University of Florida

    Coronary Artery Disease

    January 2012

    NCT01852214

    University of Florida

    Diabetes Mellitus-Coronary Artery Disease

    February 2013

    NCT01365221

    Medstar Health Research Institute

    Acute Coronary Syndrome

    December 2010

    Phase 4

    NCT01531114

    Gennaro Sardella-University of Roma La Sapienza

    ST-Elevation Myocardial Infarction

    May 2013

    Phase 3

    NCT01641510

    Dong-A University

    Acute Coronary Syndromes

    October 2013

    Phase 3

    NCT01591317

    Eli Lilly and Company

    Healthy Volunteers

    March 2009

    Phase 1

    NCT02070159

    Dong-A University

    Coronary Artery Disease

    December 2011

    Phase 3

    NCT01465828

    Gennaro Sardella-University of Roma La Sapienza

    Acute Coronary Syndrome

    October 2011

    Phase 3

    NCT02075125

    Dong-A University

    ST-Segment Elevation Myocardial Infarction

    January 2014

    Phase 3

    NCT01778842

    Gennaro Sardella-University of Roma La Sapienza

    Coronary Artery Disease

    March 2013

    Phase 3

    NCT01876797

    Asan Medical Center

    Healthy

    July 2013

    Phase 1

    NCT01852019

    The Medicines Company

    Coronary Artery Disease

    June 2013

    Phase 2

    NCT01430091

    Eli Lilly and Company

    Sickle Cell Disease

    September 2011

    Phase 1

    NCT01951001

    Gyeongsang National University Hospital

    Acute Coronary Syndrome-Platelet Thrombus-Bleeding

    July 2013

    Phase 4

    NCT02065479

    University of Florida

    Coronary Artery Disease

    March 2014

    Phase 4

    NCT02808767

    Faculty Hospital Kralovske Vinohrady

    Myocardial Infarction-Angioplasty, Balloon, Coronary-Platelet Aggregation Inhibitors

    January 2013

    Phase 4

    NCT00385944

    Eli Lilly and Company-Daiichi Sankyo Inc.

    Acute Coronary Syndrome

    March 2007

    Phase 2

    NCT01304472

    University of Patras

    Coronary Artery Disease (CAD)

    February 2011

    Phase 3

    NCT01790854

    David Antoniucci-A.R. CARD Onlus Foundation-Careggi Hospital

    Adverse Reaction to Antiplatelet Agent-Acute Coronary Syndrome

    November 2012

    Phase 4

    NCT01609647

    Dong-A University

    Acute Coronary Syndrome

    September 2012

    Phase 3

    NCT01789814

    Tufts Medical Center

    Coronary Artery Disease

    July 2013

    Phase 4

    NCT01587651

    Daiichi Sankyo Inc.-Eli Lilly and Company

    Coronary Artery Disease

    March 2012

    Phase 4

    NCT02016170

    University of Florida

    Coronary Artery Disease-Acute Coronary Syndrome

    March 2014

    NCT01155765

    University of Patras

    Hemodialysis-Chronic Renal Failure

    May 2010

    Phase 3

    NCT01648790

    Eli Lilly and Company-Daiichi Sankyo Inc.

    Healthy Volunteers

    July 2012

    Phase 1

    NCT01109784

    University of Patras

    Coronary Artery Disease (CAD)-Acute Coronary Syndrome (ACS)

    April 2010

    Phase 3

    NCT02507323

    Yochai Birnbaum-AstraZeneca-Baylor College of Medicine

    Cardiovascular Disease

    February 2016

    Phase 2

    NCT01463150

    University of Patras

    Platelet Reactivity

    October 2011

    Phase 4

    NCT01456364

    Deutsches Herzzentrum Muenchen

    Coronary Heart Disease

    September 2011

    Phase 4

    NCT01684813

    Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-Andaluz Health Service

    Diabetes Mellitus Type II-Acute Coronary Syndrome

    October 2012

    Phase 4

    NCT01167023

    Eli Lilly and Company-Daiichi Sankyo Inc.

    Sickle Cell Anemia

    July 2010

    Phase 2

    NCT01463163

    University of Patras

    Platelet Reactivity

    October 2011

    Phase 4

    NCT01794000

    Eli Lilly and Company-Daiichi Sankyo Inc.

    Sickle Cell Disease

    April 2013

    Phase 3

    NCT02075268

    Asan Medical Center

    Healthy

    January 2014

    Phase 1

    NCT02215993

    Federal University of São Paulo

    Acute Coronary Syndrome-Platelet Function

    July 2013

    Phase 4

    NCT01543932

    University of Roma La Sapienza

    Coronary Artery Disease

    July 2012

    Phase 3

    NCT02193971

    Seoul National University Hospital-Boston Scientific Korea Co. Ltd-Dio-Terumo Corporation

    Acute Coronary Syndrome

    July 2014

    Phase 4

    NCT01338909

    University of Patras

    Myocardial Infarction

    April 2011

    Phase 3

    NCT01869309

    LifeBridge Health-AstraZeneca

    Coronary Artery Disease

    January 2014

    Phase 4

    NCT01774838

    University of Cologne

    Acute Coronary Syndrome-Unstable Angina

    October 2014

    Phase 3

    NCT01944800

    Deutsches Herzzentrum Muenchen-Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

    Acute Coronary Syndrome (ACS)

    September 2013

    相关文章

      网友评论

        本文标题:Prasugrel Maleic acid

        本文链接:https://www.haomeiwen.com/subject/ccmvbxtx.html